CapsoView (CVV); CapsoCloud (CLD)
CapsoVision, Inc. · Decision date Sep 25, 2026
What did the FDA decide?
CapsoVision, Inc. received a substantially equivalent (SESE) decision for K254230 on September 25, 2026, covering CapsoView (CVV) and CapsoCloud (CLD), classified under 21 CFR 876.1540 as gastrointestinal capsule endoscopy analysis software, product code QZF, in the Gastroenterology/Urology specialty. The submission adds AI-assisted reading tools to the existing CapsoCam Plus (SV-3) reading software cleared under K242643, without changes to that hardware. The listed primary predicate is Ankon Technologies' NaviCam ProScan (DEN230027); DigestAID's Deep Capsule (K250655) is listed as a reference device.
The described tools mark suspected abnormal frames with bounding boxes, suggest digestive tract landmarks, and identify obscured frames; results are stored as metadata without altering video frames. The stated indications cover adults and pediatric patients over two years of age imaged for suspected small bowel bleeding, and the summary states the tools do not replace clinician interpretation. The summary notes the patient-population difference from the predicate reflects study populations rather than a difference in intended use. The provided excerpts do not include performance data, so the basis for the equivalence determination is not shown here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 25, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254230
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- CapsoVision, Inc.
- Product code
- QZF
- Decision code
- SESE
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Gastrointestinal Capsule Endoscopy Analysis Software Device.
- Applicant
- CapsoVision, Inc.
- Product code
- QZF
- FDA device class
- 2
FDA decision timeline
K254230 received
Application receipt date recorded by FDA.
K254230 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
CapsoVision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Saratoga, CA
Sources and methodology
- Original FDA record: K254230
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records